1
|
Méndez-Andino JL, Wos JA. MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today 2007; 12:972-9. [DOI: 10.1016/j.drudis.2007.08.010] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2007] [Revised: 08/08/2007] [Accepted: 08/21/2007] [Indexed: 10/22/2022]
|
2
|
Su J, Tang H, McKittrick BA, Gu H, Guo T, Qian G, Burnett DA, Clader JW, Greenlee WJ, Hawes BE, O'neill K, Spar B, Weig B, Kowalski T, Sorota S. Synthesis of novel bicyclo[4.1.0]heptane and bicyclo[3.1.0]hexane derivatives as melanin-concentrating hormone receptor R1 antagonists. Bioorg Med Chem Lett 2007; 17:4845-50. [PMID: 17604169 DOI: 10.1016/j.bmcl.2007.06.048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Revised: 06/11/2007] [Accepted: 06/13/2007] [Indexed: 10/23/2022]
Abstract
To address the hERG liability of MCHR1 antagonists such as 1 and 2, new analogs such as 4 and 5 that incorporated a polar heteroaryl group were designed and synthesized. Biological evaluation confirmed that these new analogs retained MCH R1 activity with greatly attenuated hERG liabilities as indicated in the Rb efflux assay.
Collapse
Affiliation(s)
- Jing Su
- Department of Chemical Research, Schering-Plough Research Institute K15 2545, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Su J, McKittrick BA, Tang H, Burnett DA, Clader JW, Greenlee WJ, Hawes BE, O'Neill K, Spar B, Weig B, Kowalski T, Sorota S, Li C, Liu T. SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: Taming hERG. Bioorg Med Chem 2007; 15:5369-85. [PMID: 17572094 DOI: 10.1016/j.bmc.2007.05.068] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2007] [Revised: 05/23/2007] [Accepted: 05/29/2007] [Indexed: 11/18/2022]
Abstract
To improve the ex vivo potency of MCH inhibitor 1a and to address its hERG liability, a structure-activity study was carried out, focusing on three regions of the lead structure. Introduction of new side chains with basic nitrogen improved in vitro and ex vivo bindings. Many potent compounds with K(i)<10nM were discovered (compounds 6a-j) and several compounds (14-17) had excellent ex vivo binding at 6h and 24h. Attenuating the basicity of nitrogen on the side chain, and in particular, introduction of a polar group such as aminomethyl on the distal phenyl ring significantly lowered the hERG activity. Further replacement of the distal phenyl group with heteroaryl groups in the cyclohexene series provided compounds such as 28l with excellent ex vivo activity with much reduced hERG liability.
Collapse
Affiliation(s)
- Jing Su
- Department of Chemical Research, Schering-Plough Research Institute K15 2545, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Zhang M, Tamiya J, Nguyen L, Rowbottom MW, Dyck B, Vickers TD, Grey J, Schwarz DA, Heise CE, Haelewyn J, Mistry MS, Goodfellow VS. Thienopyrimidinone bis-aminopyrrolidine ureas as potent melanin-concentrating hormone receptor-1 (MCH-R1) antagonists. Bioorg Med Chem Lett 2007; 17:2535-9. [PMID: 17329101 DOI: 10.1016/j.bmcl.2007.02.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2007] [Revised: 02/05/2007] [Accepted: 02/06/2007] [Indexed: 10/23/2022]
Abstract
A series of thienopyrimidinone bis-aminopyrrolidine ureas were designed, synthesized, and evaluated for their ability to bind melanin-concentrating hormone receptor-1. These compounds exhibit potent binding affinity (K(i)=3 nM) and good in vitro metabolic stability.
Collapse
Affiliation(s)
- Mingzhu Zhang
- Department of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., 12790 El Camino Real, San Diego, CA 92130, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Goodnow RA, Gillespie P. 1Hit and Lead Identification: Efficient Practices for Drug Discovery. PROGRESS IN MEDICINAL CHEMISTRY 2007; 45:1-61. [PMID: 17280901 DOI: 10.1016/s0079-6468(06)45501-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Robert A Goodnow
- Discovery Chemistry, Roche Research Center, Nutley, NJ 07110-1199, USA
| | | |
Collapse
|
6
|
Sasikumar TK, Qiang L, Burnett DA, Greenlee WJ, Hawes BE, Kowalski TJ, O'Neill K, Spar BD, Weig B. Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases. Bioorg Med Chem Lett 2006; 16:5427-31. [PMID: 16889961 DOI: 10.1016/j.bmcl.2006.07.058] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2006] [Revised: 07/14/2006] [Accepted: 07/18/2006] [Indexed: 11/20/2022]
Abstract
A series of novel aminobenzimidazoles was prepared and evaluated for h-MCH-R1 antagonist properties. Most of the compounds showed excellent h-MCH-R1 binding affinity as well as mouse ex vivo binding. Compounds 9 and 18 were active in mouse DIO studies at 30mpk.
Collapse
Affiliation(s)
- T K Sasikumar
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Hudson S, Kiankarimi M, Rowbottom MW, Vickers TD, Wu D, Pontillo J, Ching B, Dwight W, Goodfellow VS, Schwarz D, Heise CE, Madan A, Wen J, Ban W, Wang H, Wade WS. Synthesis and structure–activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2. Bioorg Med Chem Lett 2006; 16:4922-30. [PMID: 16824755 DOI: 10.1016/j.bmcl.2006.06.049] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2006] [Revised: 06/13/2006] [Accepted: 06/14/2006] [Indexed: 11/20/2022]
Abstract
The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compounds from this series exhibited considerable binding affinity (Ki = 1 nM) and functional activity at MCH-R1, acceptable CYP2D6 inhibition, and good rat brain exposure.
Collapse
Affiliation(s)
- Sarah Hudson
- Department of Medicinal Chemistry, Neurocrine Biosciences Inc., 12790 El Camino Real, San Diego, CA 92130, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Rowbottom MW, Vickers TD, Dyck B, Grey J, Tamiya J, Zhang M, Kiankarimi M, Wu D, Dwight W, Wade WS, Schwarz D, Heise CE, Madan A, Fisher A, Petroski R, Goodfellow VS. Synthesis and structure–activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 1. Bioorg Med Chem Lett 2006; 16:4450-7. [PMID: 16814542 DOI: 10.1016/j.bmcl.2006.06.045] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2006] [Revised: 06/12/2006] [Accepted: 06/12/2006] [Indexed: 10/24/2022]
Abstract
The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compounds from this series exhibited potent binding affinity and functional activity at MCH-R1, and good oral bioavailability in rat.
Collapse
Affiliation(s)
- Martin W Rowbottom
- Department of Medicinal Chemistry, Neurocrine Biosciences Inc., San Diego, CA 92130, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Witty DR, Bateson JH, Hervieu GJ, Jeffrey P, Johnson CN, Muir AI, O'Hanlon PJ, Stemp G, Stevens AJ, Thewlis KM, Wilson S, Winborn KY. SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): Discovery of antagonist SB-568849. Bioorg Med Chem Lett 2006; 16:4865-71. [PMID: 16839761 DOI: 10.1016/j.bmcl.2006.06.056] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2006] [Revised: 06/14/2006] [Accepted: 06/15/2006] [Indexed: 11/29/2022]
Abstract
We report here the discovery of a class of MCH R1 ligands based on a biphenyl carboxamide template. A docked-in model is presented indicating key interactions in the putative binding site of the receptor. Parallel high throughput synthetic techniques were utilised to allow rapid exploration of the structure-activity relationship around this template, leading to compound SB-568849 which possessed good receptor affinity and selectivity. This compound proved to be an antagonist with stability in vivo, an acceptable brain-blood ratio and oral bioavailability.
Collapse
Affiliation(s)
- David R Witty
- GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Dyck B, Zhao L, Tamiya J, Pontillo J, Hudson S, Ching B, Heise CE, Wen J, Norton C, Madan A, Schwarz D, Wade W, Goodfellow VS. Substituted chromones and quinolones as potent melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem Lett 2006; 16:4237-42. [PMID: 16762549 DOI: 10.1016/j.bmcl.2006.05.075] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2006] [Revised: 05/19/2006] [Accepted: 05/22/2006] [Indexed: 11/20/2022]
Abstract
A series of substituted chromones were designed, synthesized, and evaluated for their ability to bind melanin-concentrating hormone receptor 1. Compounds with subnanomolar binding affinity and 66% oral bioavailability in rats were discovered.
Collapse
Affiliation(s)
- Brian Dyck
- Department of Medicinal Chemistry, Neurocrine Biosciences Inc., San Diego, CA 92130, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Blackburn C, LaMarche MJ, Brown J, Che JL, Cullis CA, Lai S, Maguire M, Marsilje T, Geddes B, Govek E, Kadambi V, Doherty C, Dayton B, Brodjian S, Marsh KC, Collins CA, Kym PR. Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists. Bioorg Med Chem Lett 2006; 16:2621-7. [PMID: 16524729 DOI: 10.1016/j.bmcl.2006.02.044] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2005] [Revised: 02/14/2006] [Accepted: 02/15/2006] [Indexed: 11/25/2022]
Abstract
Several potent, functionally active MCHr1 antagonists derived from quinolin-2(1H)-ones and quinazoline-2(1H)-ones have been synthesized and evaluated. Pyridylmethyl substitution at the quinolone 1-position results in derivatives with low-nM binding potency and good selectivity with respect to hERG binding.
Collapse
|
12
|
Vasudevan A, Souers AJ, Freeman JC, Verzal MK, Gao J, Mulhern MM, Wodka D, Lynch JK, Engstrom KM, Wagaw SH, Brodjian S, Dayton B, Falls DH, Bush E, Brune M, Shapiro RD, Marsh KC, Hernandez LE, Collins CA, Kym PR. Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists. Bioorg Med Chem Lett 2005; 15:5293-7. [PMID: 16203136 DOI: 10.1016/j.bmcl.2005.08.049] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2005] [Revised: 08/05/2005] [Accepted: 08/10/2005] [Indexed: 11/20/2022]
Abstract
The synthesis and biological evaluation of novel 3-amino indazole melanin concentrating hormone receptor-1 antagonists are reported, several of which demonstrated functional activity of less than 100nM. Compounds 19 and 28, two of the more potent compounds identified in this study, were characterized by high exposure in the brain and demonstrated robust efficacy when dosed in diet-induced obese mice.
Collapse
Affiliation(s)
- Anil Vasudevan
- Metabolic Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|